Cytokinetics, Incorporated (CYTK)

Cytokinetics Statistics

Total Valuation

Cytokinetics has a market cap or net worth of $5.11 billion. The enterprise value is $4.96 billion.

Market Cap	5.11B
Enterprise Value	4.96B

Important Dates

The next estimated earnings date is Wednesday, May 7, 2025, after market close.

Earnings Date	May 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Cytokinetics has 118.41 million shares outstanding. The number of shares has increased by 16.01% in one year.

Current Share Class	118.41M
Shares Outstanding	118.41M
Shares Change (YoY)	+16.01%
Shares Change (QoQ)	+0.33%
Owned by Insiders (%)	0.48%
Owned by Institutions (%)	111.84%
Float	117.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	261.79
Forward PS	133.97
PB Ratio	-37.78
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	268.56
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.17

Current Ratio	6.17
Quick Ratio	6.08
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.20

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-30.11%
Return on Invested Capital (ROIC)	-57.92%
Return on Capital Employed (ROCE)	-43.88%
Revenue Per Employee	$37,096
Profits Per Employee	-$1.18M
Employee Count	498
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -39.52% in the last 52 weeks. The beta is 0.95, so Cytokinetics's price volatility has been similar to the market average.

Beta (5Y)	0.95
52-Week Price Change	-39.52%
50-Day Moving Average	45.77
200-Day Moving Average	51.49
Relative Strength Index (RSI)	44.18
Average Volume (20 Days)	1,687,978

Short Selling Information

The latest short interest is 14.22 million, so 12.01% of the outstanding shares have been sold short.

Short Interest	14.22M
Short Previous Month	14.07M
Short % of Shares Out	12.01%
Short % of Float	12.07%
Short Ratio (days to cover)	7.82

Income Statement

In the last 12 months, Cytokinetics had revenue of $18.47 million and -$589.53 million in losses. Loss per share was -$5.26.

Revenue	18.47M
Gross Profit	-320.93M
Operating Income	-536.25M
Pretax Income	-545.28M
Net Income	-589.53M
EBITDA	-526.72M
EBIT	-536.25M
Loss Per Share	-$5.26

Balance Sheet

The company has $1.08 billion in cash and $923.18 million in debt, giving a net cash position of $152.83 million or $1.29 per share.

Cash & Cash Equivalents	1.08B
Total Debt	923.18M
Net Cash	152.83M
Net Cash Per Share	$1.29
Equity (Book Value)	-135.37M
Book Value Per Share	-1.15
Working Capital	928.27M

Cash Flow

In the last 12 months, operating cash flow was -$395.89 million and capital expenditures -$3.91 million, giving a free cash flow of -$399.80 million.

Operating Cash Flow	-395.89M
Capital Expenditures	-3.91M
Free Cash Flow	-399.80M
FCF Per Share	-$3.38

Margins

Gross Margin	n/a
Operating Margin	-2,902.72%
Pretax Margin	-3,191.11%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Cytokinetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.01%
Shareholder Yield	n/a
Earnings Yield	-11.53%
FCF Yield	-7.82%

Analyst Forecast

The average price target for Cytokinetics is $82.00, which is 89.86% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$82.00
Price Target Difference	89.86%
Analyst Consensus	Strong Buy
Analyst Count	17
Revenue Growth Forecast (5Y)	145.19%
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on June 25, 2013. It was a reverse split with a ratio of 0.1666666:1.

Last Split Date	Jun 25, 2013
Split Type	Reverse
Split Ratio	0.1666666:1

Scores

Cytokinetics has an Altman Z-Score of -0.53 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.53
Piotroski F-Score	4